See more : PT Panin Sekuritas Tbk (PANS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Lincoln Pharmaceuticals Limited (LINCOPH.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lincoln Pharmaceuticals Limited, a leading company in the industry within the sector.
- Equator Beverage Company (MOJO) Income Statement Analysis – Financial Results
- JAKS Resources Berhad (4723.KL) Income Statement Analysis – Financial Results
- Amines & Plasticizers Limited (AMNPLST.NS) Income Statement Analysis – Financial Results
- Qinhuangdao Port Co., Ltd. (601326.SS) Income Statement Analysis – Financial Results
- Hon Kwok Land Investment Company, Limited (0160.HK) Income Statement Analysis – Financial Results
Lincoln Pharmaceuticals Limited (LINCOPH.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Lincoln Pharmaceuticals Limited
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative, as well as dermatologist preparations, gynecological products, gastrointestinal rang, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It also offers branded generics. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 5.06B | 4.69B | 4.15B | 3.77B | 3.57B |
| Cost of Revenue | 3.75B | 3.24B | 2.95B | 2.75B | 2.62B |
| Gross Profit | 1.31B | 1.45B | 1.20B | 1.03B | 953.19M |
| Gross Profit Ratio | 25.92% | 30.96% | 28.87% | 27.26% | 26.66% |
| Research & Development | 117.69M | 0.00 | 93.63M | 83.00M | 89.38M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 384.41M | 557.97M | 435.94M | 422.91M | 312.94M |
| Other Expenses | -29.02M | -33.00M | 50.82M | -14.99M | -21.57M |
| Operating Expenses | 531.12M | 590.97M | 478.75M | 520.89M | 423.89M |
| Cost & Expenses | 4.28B | 3.83B | 3.43B | 3.27B | 3.05B |
| Interest Income | 61.71M | 50.28M | 22.37M | 15.00M | 11.91M |
| Interest Expense | 20.30M | 14.51M | 15.62M | 20.18M | 39.97M |
| Depreciation & Amortization | -91.66M | -80.88M | -75.60M | -73.26M | -67.01M |
| EBITDA | 871.58M | 941.21M | 795.75M | 581.04M | 596.31M |
| EBITDA Ratio | 17.23% | 20.08% | 19.16% | 15.40% | 16.68% |
| Operating Income | 779.92M | 860.33M | 720.15M | 507.78M | 529.30M |
| Operating Income Ratio | 15.42% | 18.35% | 17.34% | 13.46% | 14.81% |
| Total Other Income/Expenses | 224.88M | 99.06M | 117.06M | 164.55M | 92.64M |
| Income Before Tax | 1.00B | 959.39M | 837.21M | 672.32M | 621.94M |
| Income Before Tax Ratio | 19.86% | 20.46% | 20.16% | 17.82% | 17.40% |
| Income Tax Expense | 275.81M | 265.84M | 214.71M | 157.66M | 134.56M |
| Net Income | 728.99M | 693.55M | 622.50M | 514.39M | 487.10M |
| Net Income Ratio | 14.41% | 14.79% | 14.99% | 13.63% | 13.63% |
| EPS | 36.40 | 34.63 | 31.08 | 25.72 | 24.36 |
| EPS Diluted | 36.40 | 34.63 | 31.08 | 25.72 | 24.36 |
| Weighted Avg Shares Out | 20.03M | 20.03M | 20.03M | 20.00M | 20.00M |
| Weighted Avg Shares Out (Dil) | 20.03M | 20.03M | 20.03M | 20.00M | 20.00M |
Source: https://incomestatements.info
Category: Stock Reports